[
  {
    "ts": null,
    "headline": "Labcorp’s New Alzheimer’s Blood Test Might Change The Case For Investing In Labcorp Holdings (LH)",
    "summary": "In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying symptomatic patients aged 55+ who are unlikely to have amyloid pathology. This test broadens access to Alzheimer’s assessment through a simple blood draw, potentially easing specialist bottlenecks and shifting more initial evaluation into primary care. Next, we’ll examine how expanding Alzheimer’s blood...",
    "url": "https://finnhub.io/api/news?id=51d27272f45a58334d5971a17bb65011e8372e6712de667d49f62e4c38fc4be2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771089124,
      "headline": "Labcorp’s New Alzheimer’s Blood Test Might Change The Case For Investing In Labcorp Holdings (LH)",
      "id": 139098480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying symptomatic patients aged 55+ who are unlikely to have amyloid pathology. This test broadens access to Alzheimer’s assessment through a simple blood draw, potentially easing specialist bottlenecks and shifting more initial evaluation into primary care. Next, we’ll examine how expanding Alzheimer’s blood...",
      "url": "https://finnhub.io/api/news?id=51d27272f45a58334d5971a17bb65011e8372e6712de667d49f62e4c38fc4be2"
    }
  }
]